Cumberland Pharmaceuticals, INC.
At a glance
Employees20-99
In business sinceNot reported
HeadquartersNashville, TN
US patents33
SAM.gov UEIM2ZXA6LYJ3S5
CAGE code3VFM4
Incorporated inTN
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
33 US patents granted 2004–2024, 4 of them in the five years to SEP 2025.
Pharmaceuticals 33
- Compositions and methods of treating cardiac fibrosis with ifetrobanUS 12,161,632 · granted DEC 10, 2024
- Injectable ibuprofen formulationUS 11,806,400 · granted NOV 7, 2023
- Thromboxane receptor antagonists in AERD/asthmaUS 11,571,412 · granted FEB 7, 2023
- Compositions and methods of treating cardiac fibrosis with ifetrobanUS 10,925,860 · granted FEB 23, 2021
- Doses and methods for administering telavancinUS 10,751,383 · granted AUG 25, 2020
Newest 5 shown · Granted to Cumberland Pharmaceuticals Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | Nashville | TN | 20–99 | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.